MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

T-DM1

  • Home
  • T-DM1
Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib
Posted inInternal Medicine Oncology Specialties

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

Posted by By MedXY 10/18/2025
This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.
Read More
  • Deep Learning on CT Scans Enhances Prognostication of Interstitial Lung Abnormalities
  • Ocular Metastasis Over Four Decades: Clinical Patterns, Survival, and Therapeutic Outcomes in 569 Patients
  • HPV Positivity in Keratinizing Nasopharyngeal Carcinoma: Implications for Prognosis and Clinical Practice
  • Impact of Patient-Level Social Determinants on Colon Cancer Outcomes: A Novel Prognostic Measure Within an Integrated Health Network
  • Adjunctive Metformin with Progestin in Fertility-Sparing Treatment of Endometrial Neoplasia: Insights from the FELICIA Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top